Home » Chronic Conditions » Gaucher Disease

Gaucher Disease Infusion Treatment in the Southeast

 

Comprehensive support to help you manage your condition – physically, financially, and spiritually.

Learn More

Gaucher’s Disease Medications

    • 35+ Years of Pharmacy Heritage: Supporting patients with specialty pharmacy and infusion care experience across the Southeast.
    • 30+ Regional Infusion Centers: Serving patients throughout Tennessee, Kentucky, Georgia, Mississippi, and Virginia.
    • PharmD-Led Clinical Supervision: Coordinated by specialized pharmacists and experienced infusion nurses.
    • Complete Insurance Coordination: Assistance with benefits verification, prior authorizations, and copay support programs.
    • Private Patient Suites: Comfortable infusion environments with recliners, WiFi, and attentive clinical staff.

    How Enzyme Replacement Therapy Treats Gaucher Disease

    Enzyme replacement therapy (ERT) is a primary Gaucher disease infusion treatment designed to replace the missing or deficient glucocerebrosidase enzyme. Delivered through scheduled IV infusions, this therapy helps address the underlying cause of Gaucher disease rather than only managing symptoms associated with the condition.

    Clinical Goals and Limitations

    The primary goal of therapy is to reduce the buildup of fatty substances in the body’s cells. Specialists often monitor treatment progress through factors such as red blood cell and platelet counts, liver and spleen enlargement, bone pain, and overall symptom stability.

    Because enzyme replacement therapies do not cross the blood-brain barrier, they are not intended to treat neurological symptoms associated with Gaucher disease. 

    TwelveStone Health Partners focuses on safe medication administration, coordinated scheduling, and ongoing infusion support. Our team helps patients navigate insurance verification, appointment coordination, chronic condition infusion support and communication with their prescribing specialists before treatment begins.

    Comparing FDA-Approved Enzyme Replacement Therapies

    Three FDA-approved enzyme replacement therapies are commonly prescribed for Gaucher disease infusion treatment: imiglucerase (Cerezyme), velaglucerase alfa (VPRIV), and taliglucerase alfa (Elelyso).

    While each therapy replaces the deficient enzyme associated with Gaucher disease, they differ in formulation, manufacturing methods, approved age ranges, and infusion schedules. For example, Cerezyme is produced using mammalian cell cultures, VPRIV uses a human cell line, and Elelyso is plant-cell based.

    Because every patient’s needs are different, your specialist will determine the appropriate medication, dosing schedule, and infusion frequency for your condition. As with many IV therapies, infusion-related reactions can occur, which is why physicians may recommend monitored administration during early treatments. 

    TwelveStone coordinates infusion support for prescribed Gaucher disease therapies and helps manage scheduling, insurance approvals, and site-of-care coordination. Patients may receive treatment in one of our regional infusion suites or through eligible home infusion services.

    IV infusion pump with fluid bag and medical supplies in a clinic setting during patient infusion therapy treatment

    Selecting Your Infusion Setting: Suite or Home Care

    Choosing the right infusion setting involves balancing convenience, safety, insurance requirements, and personal comfort. Your medical team can help determine whether a clinical infusion suite or home infusion care is the best fit for your treatment plan.

    Clinical Suite Infusion

    Our infusion center suites provide a professionally monitored setting for Gaucher disease infusion treatment. Registered nurses supervise your therapy, monitor for infusion reactions, and help ensure safe medication administration throughout your appointment. Patients looking for a nearby location can explore our infusion centers map tool.

    Home Infusion Criteria

    Home infusion services may be appropriate for clinically stable patients who have tolerated treatment well and meet insurance eligibility requirements. Your physician and care coordination team will evaluate whether home administration is a safe option for your treatment plan.

    Vascular Access Considerations

    Your specialist may recommend either a peripheral IV or an implanted port for long-term infusion therapy. Each option carries different considerations related to comfort, reliability, infection risk, and long-term vein health.

    Because Gaucher disease can affect blood counts and overall health status, your prescribing physician will help determine the safest vascular access approach for your care needs.

    View through glass into TwelveStone Health Partners reception and waiting area, with the logo and office hours printed on the door.

    A Structured Approach to Your Infusion Care

    Our clinical team follows a structured care coordination process to help keep your Gaucher disease infusion treatment organized, safe, and consistent from referral through ongoing therapy.

    Referral and Intake

    We receive your prescription and establish your patient profile.

    Benefits Verification and Scheduling

    Our coordinators confirm insurance coverage and schedule your infusion appointments.

    Baseline Evaluation

    A registered nurse reviews your health history and records baseline vital signs before treatment.

    Medication Administration

    Your infusion is administered under clinical supervision by experienced nursing staff.

    The Post-Infusion Follow-Up

    Our team documents the session and communicates updates with your prescribing physician as needed.

    Infusion reactions can occur during treatment, but our nursing staff is trained to respond quickly and follow physician-directed safety protocols when needed. Depending on your care plan, nurses may slow or pause the infusion and administer supportive medications if reactions occur.

    Patients receiving treatment in our private infusion suites have access to comfortable recliners, televisions, WiFi, and supportive clinical staff throughout their appointments. TwelveStone also offers additional patient support resources, including chaplain services for individuals seeking faith-based care support.

    nurse at computer

    Navigating Costs and Insurance for Gaucher ERT

    Because enzyme replacement therapies are specialty medications, insurance coordination and financial planning are important parts of Gaucher disease infusion treatment. Many patients use a combination of commercial insurance coverage, manufacturer assistance programs, and copay support to help manage treatment costs.

    • Benefits Verification: Confirming your plan covers the prescribed medication.
    • Prior Authorization: Submitting clinical documentation required by your insurer.
    • Site-of-Care Approval: Determining eligibility for infusion center or home administration.
    • Ongoing Reauthorization: Maintaining approval for continued treatment coverage.

    TwelveStone Health Partners works with commercial insurance plans, Medicare, and Medicaid to help coordinate these requirements. Our team can also help identify available copay assistance and manufacturer support programs that may reduce out-of-pocket expenses.

    If you experience changes in symptoms near the end of your infusion cycle, document those concerns and discuss them with your prescribing specialist. Consistent communication can help your care team coordinate scheduling and treatment timing more effectively.

    ★★★★★ Rated 4.9 stars from 3000+ patient reviews

    Organizational Resources

    The National Gaucher Foundation (NGF) is an independent nonprofit dedicated to serving U.S. patients with Gaucher disease and their families. Through financial support, educational programming, patient services, and collaboration with medical professionals, NGF empowers Gaucher patients to live a better today.

    Learn more

    The Gaucher Community Alliance (GCA) is a 501(c)(3) non-profit organization for the patient community by the patient community. Our mission is to support patients with Gaucher disease and their families through peer-to-peer support and education, advocacy, patient and family resources, and networking

    Learn more

    The International Gaucher Alliance (IGA) is a patient-led international organisation that has become the ‘go to’ global voice for over 90% of the Gaucher community and has built its reputation through listening to and delivering outcomes that have impacted patients and their carers’ lives.

    Learn more

    New Patient Resources

    Frequently Asked Questions About Gaucher Disease Infusion

    Yes, some patients may qualify for home infusion therapy after demonstrating clinical stability and tolerating treatment without significant infusion reactions. Eligibility also depends on physician approval, insurance authorization, and the availability of trained nursing supervision during treatment.

    A typical Gaucher enzyme infusion may take between one and two hours, depending on the prescribed medication, infusion rate, and your individual treatment plan. Your clinical team will monitor your response throughout the appointment and adjust administration speed if needed for safety or comfort.

    Infusion reactions are physical responses that may occur during treatment and can range from mild symptoms, such as itching or headache, to more serious reactions that require medical attention. If a reaction occurs, our nursing team can pause or slow the infusion and administer supportive medications according to physician-approved protocols.

    Not all patients require an implanted port for long-term infusion therapy. Some individuals continue treatment through peripheral IV access, while others prefer ports for convenience and vein preservation. Your specialist can help evaluate the risks and benefits of each option based on your treatment needs and health history.

    Out-of-pocket costs for Gaucher disease infusion treatment vary based on insurance coverage, deductibles, and copay requirements. Our financial coordination team helps patients understand expected costs, complete benefits verification, and explore available copay assistance or manufacturer support programs.

    These medications are all enzyme replacement therapies designed to treat Gaucher disease, but they differ in how they are manufactured and administered. Cerezyme is produced using mammalian cells, VPRIV uses a human cell line, and Elelyso is developed using plant-cell technology. Your specialist will determine which therapy is most appropriate for your condition and treatment history.

    To begin treatment, your specialist can send your prescription directly to the TwelveStone intake team. From there, we coordinate benefits verification, scheduling, and site-of-care planning to help you start therapy as smoothly as possible.